Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

Unlocking Immunotherapy Potential with CapCure: A Novel Chemical Antagonist of PSME4

Objetivo

Immunotherapy has transformed cancer treatment, yet many patients fail to benefit because their tumors develop intrinsic mechanisms to block immune attack. Recent discoveries from our ERC-funded work revealed that the proteasome, a central protein degradation system, can be hijacked by tumors to suppress immune recognition and promote an immunosuppressive environment.

This Proof of Concept project aims to translate these findings into a novel therapeutic approach. We will develop and validate small molecules that block this tumor-associated mechanism, restoring the ability of the immune system to detect and eliminate cancer cells. Our focus will be on two major cancers with a high unmet need, non–small cell lung cancer and aggressive breast cancer, where resistance to immunotherapy remains a critical challenge.

The project will combine the development of a small molecule which will allow us to modulate proteasomes activity, together with preclinical validation, and a commercialization pathway including intellectual property protection and market analysis. By the end of the project, we expect to deliver optimized drug candidates and a biomarker-guided framework to identify patients most likely to benefit.

Ultimately, this work seeks to establish a new therapeutic class that enhances the effectiveness of existing immunotherapies, with the long-term goal of improving outcomes for patients whose cancers currently remain resistant to treatment.

Ámbito científico (EuroSciVoc)

Programa(s)

Tema(s)

Régimen de financiación

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) ERC-2026-POC

Ver todos los proyectos financiados en el marco de esta convocatoria

Institución de acogida

WEIZMANN INSTITUTE OF SCIENCE
Aportación neta de la UEn
€ 150 000,00
Coste total
Sin datos

Beneficiarios (1)